Venus Remedies Ltd. - Research Center
526953 VENUSREM Group (B) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 21 | Mar ' 20 | Mar ' 19 | Mar ' 18 | Mar ' 17 | |
|---|---|---|---|---|---|
| Sales | 514.62 | 322.36 | 301.84 | 355.07 | 375.45 |
| Operating profit | 46.86 | 43.07 | 34.29 | 43.56 | 75.04 |
| Interest | 12.73 | 13.05 | 25.15 | 34.98 | 33.56 |
| Gross profit | 51.90 | 33.60 | 13.65 | 9.30 | 42.27 |
| EPS (Rs) | 43.97 | -6.67 | -21.97 | -21.54 | 3.85 |
Annual
results in details
| Mar ' 21 | Mar ' 20 | Mar ' 19 | Mar ' 18 | Mar ' 17 | |
|---|---|---|---|---|---|
| Other income | 17.76 | 3.58 | 4.51 | 0.72 | 0.79 |
| Stock adjustment | -7.36 | 6.21 | -7.98 | -0.30 | 0.51 |
| Raw material | 344.04 | 170.60 | 189.76 | 205.72 | 221.12 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 35.89 | 33.79 | 30.26 | 27.82 | 25.10 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | 79.32 | 54.44 | 40.85 | - | - |
| Research and development expenses | 15.87 | 14.25 | 14.65 | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | - | - | - | 78.26 | 53.68 |
| Provisions made | - | - | - | - | - |
| Depreciation | 34.28 | 31.05 | 32.95 | 32.73 | 41.22 |
| Taxation | -13.21 | 1.96 | -1.15 | 3.16 | -3.70 |
| Net profit / loss | 54.27 | -8.23 | -27.11 | -26.58 | 4.75 |
| Extra ordinary item | 23.44 | -8.81 | -8.96 | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 12.34 | 12.34 | 12.34 | 12.34 | 12.34 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 9.11 | 13.36 | 11.36 | 12.27 | 19.99 |
| GPM (%) | 9.75 | 10.31 | 4.46 | 2.62 | 11.23 |
| NPM (%) | 10.19 | -2.52 | -8.85 | -7.47 | 1.26 |
Mutual Fund Selector
Find the fund that is right for you
© 2022 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis